CSPC Megalith Biopharmaceutical Co., Ltd. et al. vs. Shanghai Miracogen Inc. et al.

Explore the PTAB proceeding IPR2025-00685 filed by CSPC Megalith Biopharmaceutical Co., Ltd. et al. on 2025-03-03. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Proceeding Overview

Proceeding Number

IPR2025-00685

Filing Date

2025-03-03

Accorded Filing Date

2025-03-03

Institution Decision Date

2025-10-14

Last Modified Date

2026-10-08

Proceeding Type

IPR

Termination Date

2026-10-08

Trial Status

Final Written Decision

Parties & Counsel

Petitioner

CSPC Megalith Biopharmaceutical Co., Ltd. et al.

Represented By

Chen, Joeet al

Patent Owner / Respondent

Shanghai Miracogen Inc. et al.

Represented By

Ponder, Christopheret al

Tribunal & Venue

Tribunal

Patent Trial and Appeal Board (USPTO)

Technology Center

TC 1600 - Biotechnology & Organic Chemistry

Patent Information

1 Patent Involved

Respondent Application Number 15550995

Respondent Patent Number 10792370

External Links

Espacenet

Google Patents

Respondent Inventor Chaohong Hu

Respondent Tech Center TC 1600 - Biotechnology & Organic Chemistry

Address and Attorney/Agent Information

40 Registered Practitioners

Power of Attorney & Correspondence

Firm / Entity Name SEED INTELLECTUAL PROPERTY LAW GROUP LLP

Customer Number 500

Address 701 FIFTH AVE, SUITE 5400, SEATTLE, WA, 98104, UNITED STATES

Attorney / Agent Information

Reg #	Name	Phone
33507	Karl Hermanns	206-622-4900
37376	Steven Lawrenz	206-622-4900
37801	Kevin Costanza	206-622-4900
42015	Kevan Morgan	206-622-4900
43746	Shoko Leek	206-622-4900
45030	Brooke Quist	206-694-4850
46861	Michelle Lecointe	206-622-4900
47435	Timothy Boller	206-622-4900
53937	Qing Lin	206-622-4899
54150	Hai Han	206-622-4900
54459	Bobby Soltani	206-622-4900
57933	Jared Barrett	206-622-4900
59937	Eric Harwood	206-622-4900
60418	John Wakeley	203-327-6401
65314	Jessica Gritton	206-622-4900
65851	Karl Hefter	206-622-4900
65875	Hayley Talbert	206-622-4900
66397	Yiheng Li	206-622-4900
66680	David Conlee	206-622-4900
67099	Shi Liu	206-622-4900
67909	Christopher Bayne	206-859-5645
68240	Blake Kumabe	206-622-4900
68322	Michael Cooper	206-694-4900
68796	Jianping Zhang	206-876-6001
70903	Syed Abedi	206-622-4900
72203	John Morgan	206-622-4900
74673	Kazuya Toyama	737-304-0908
74699	Toby Ligon	206-622-4900
74837	Emily Ross	650-843-5521
75668	Tessa Mcclure	206-622-4900
76666	Bradley Zentz	206-859-5621
77353	Zachary Sakoi	206-622-4900
78478	Anna Mallam	206-622-4900
79439	Bilal Adra	206-622-4900
79675	Janaki Purushe	206-859-5670
81284	Michael Chernoff	206-694-4825
81573	Melina Costanza	206-622-4900
81625	Willem De Van Der Schueren	206-622-4900
82031	Hyun Kyu Lee	206-694-4893
82256	Carl Rustad	206-622-4900

Proceeding Documents

170

Final Written Decision: original FINAL

2026-10-08 FILING PARTY: BOARD

Download

Other: Hearing transcript OTHER

2026-08-04 FILING PARTY: BOARD

Download

Patent Owner's Objection to Petitioner's Demonstratives OTHER

2026-07-13 FILING PARTY: PATENT OWNER

Download

Petitioner's Demonstratives for Oral Argument OTHER

2026-07-10 FILING PARTY: PETITIONER

Download

Patent Owner's Oral Hearing Demonstratives OTHER

2026-07-10 FILING PARTY: PATENT OWNER

Download

CSPC Megalith Biopharmaceutical Co., Ltd. et al. vs. Shanghai Miracogen Inc. et al.

Proceeding Overview

Parties & Counsel

Petitioner

CSPC Megalith Biopharmaceutical Co., Ltd. et al.

Represented By

Patent Owner / Respondent

Shanghai Miracogen Inc. et al.

Represented By

Tribunal & Venue

Patent Information

Address and Attorney/Agent Information

Power of Attorney & Correspondence

Attorney / Agent Information

Proceeding Documents

Final Written Decision: original FINAL

Other: Hearing transcript OTHER

Patent Owner's Objection to Petitioner's Demonstratives OTHER

Petitioner's Demonstratives for Oral Argument OTHER

Patent Owner's Oral Hearing Demonstratives OTHER

Conference Transcript for Proceedings on July 6, 2026 Exhibit

Patent Owner's Updated Exhibit List NOTICE

Corrected Exhibit 2022 - Use of the Humanized Anti-Epidermal Growth Factor Receptor Monoclonal Antibody h-R3 Exhibit

Patent Owner's Sur-Reply OTHER

A Phase I Study of the Antibody Drug Conjugate ASG-5ME Exhibit

June 9, 2026 Deposition Transcript of Dr. Stylianos Bournazos Exhibit

Patent Owner's Updated Exhibit List NOTICE

Order Granting Patent Owner’s Unopposed Motion to Substitute Party ORDER

Order: Setting Oral Argument ORDER

Patent Owner's Power of Attorney NOTICE

Patent Owner's Updated Mandatory Notice NOTICE

Petitioner's Request for Oral Argument OTHER

Patent Owner's Request for Oral Hearing OTHER

Patent Owner's Notice of Deposition of Dr. Stylianos Bournazos NOTICE

Panel Change Order ORDER

Patent Owner's Objections to Petitioner's Evidence OTHER

Advani et al., Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin Exhibit

Stepan et al., Expression of Trop2 Cell Surface Glycoprotein in Normal and Tumor Tissues: Exhibit

Crombet et al., Pharmacological Evaluation of Humanized Anti- Epidermal Growth Factor Receptor, Exhibit

aufman et al., Dose-Escalation Trial of Milatuzumab (Humanized Anti-CD74 Monoclonal Antibody) in Multiple Myeloma, Exhibit

Verma et al., Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer Exhibit

Paz-Ares et al., Phase I Pharmacokinetic and Pharmacodynamic Dose- Escalation Study of RG7160 (GA201), Exhibit

Kim et al., Targeting Colorectal Cancer with Human Anti-EGFR Monoclonal Antibodies: Exhibit

Vectibix® (panitumumab) Injection Prescribing Information (2021) Exhibit

Deposition Transcript of Djordje Atanackovic, M.D., April 14, 2026 Exhibit

HERCEPTIN® (trastuzumab) for Injection Prescribing Information (2024) Exhibit

Schechter et al., Radiation Dosimetry of 99mTc- Labeled C225 in Patients with Squamous Cell Carcinoma Exhibit

Vallis et al., A phase I study of 99mTc-hR3 (DiaCIM), a humanized immunoconjugate Exhibit

Gerdes et al., GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody Exhibit

Bertino et al., Enhancement of cetuximab-induced antibody-dependent cellular cytotoxicity (ADCC) Exhibit

ERBITUX® (cetuximab) Injection Prescribing Information (2019) Exhibit

NIH National Library of Medicine, A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma (2016) Exhibit

Yang et al., Development of ABX-EGF, a Fully Human Anti-EGF Receptor Monoclonal Antibody, Exhibit

Chari et al., Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy, Exhibit

Leonard et al., Phase I/II Trial of Epratuzumab (Humanized Anti-CD22 Antibody) in Exhibit

Hashimoto et al., A Novel HER3-Targeting Antibody–Drug Conjugate, U3-1402, Exhibit

Mendell et al., Clinical Translation and Validation of a Predictive Biomarker for Patritumab, Exhibit

Expert Declaration of Stylianos Bournazos, Ph.D, Exhibit

Damelin et al., Evolving Strategies for Target Selection for Antibody- Drug Conjugates, Exhibit

IRESSA® (gefitinib) Tablets Prescribing Information (2018) Exhibit

Heimberger et al., The natural history of EGFR and EGFRvIII in glioblastoma patients, Exhibit

Rodríguez et al., Fc gamma receptor polymorphisms as predictive markers of Cetuximab Exhibit

Gan et al., The Epidermal Growth Factor Receptor Variant III (EGFRvIII): Exhibit

Yi et al., Function characterization of a glyco-engineered anti-EGFR monoclonal antibody Exhibit

Clynes et al., Inhibitory Fc Receptors Modulate In Vivo Cytotoxicity Against Tumor Targets, Exhibit

Wang et al., Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors Exhibit

Stenger, Adjuvant Treatment with Ado-trastuzumab Emtansine in HER2- Positive Early Breast Cancer, Exhibit

ADCETRIS® (brentuximab vedotin) Prescribing Information (2014) Exhibit

Petitioner's Reply to Patent Owner's Response REPLYTOOPP

Mullard, Maturing Antibody-Drug Conjugate Pipeline Hits 30, Nat. Rev. Drug Discov., 12:329-332 (2013) Exhibit

Van den Bent et al., Changes in the EGFR amplification and EGFRvIII expression between paired primary Exhibit

Yang et al., Cetuximab-mediated Tumor Regression Depends on Innate and Adaptive Immune Responses, Exhibit

Goldstein et al., Biological Efficacy of a Chimeric Antibody to the Epidermal Growth Factor Exhibit

Sampson et al., Immunologic Escape After Prolonged Progression-Free Survival with Epidermal Exhibit

Agensys, Inc. and Seattle Genetics, Inc., Agensys and Seattle Genetics Exhibit

TARCEVA® (erlotinib) Tablets Prescribing Information (2010) Exhibit

Lacouture et al., Skin Toxicity Evaluation Protocol with Panitumumab (STEPP), Exhibit

Galsky et al., Phase I Trial of the Prostate-Specific Membrane Antigen- Directed Immunoconjugate MLN2704 Exhibit

Moore et al., Relationship of pharmacokinetics (PK), toxicity, and initial evidence of clinical activity with IMGN853, Exhibit

Petrylak et al., A phase II trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) Exhibit